Kriya Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies across multiple therapeutic areas. Its pipeline includes programs in ophthalmology, metabolic disease and neurology built on a fully integrated proprietary manufacturing and engineering platform. The company intends to use new funding to support clinical trials of its gene therapies and to continue leveraging its research and manufacturing engine for new product development. Kriya operates from Research Triangle Park, NC. The company closed a major Series D financing to advance its clinical programs and platform utilization. Kriya Therapeutics develops gene therapies focused on prevalent diseases in ophthalmology, neurology, and metabolic disease. The company has built integrated engineering, computational, and manufacturing platforms to accelerate research, development and production of gene therapies. Proceeds from the recent financing will support clinical translation of its pipeline and further scaling of those platforms. Kriya emphasizes targeting validated biological targets and well-defined clinical endpoints to rapidly achieve proof-of-concept. Since its founding in October 2019, the company has raised over $600 million in committed capital and says its investments in infrastructure and talent have improved development efficiency. Kriya intends to translate multiple programs into the clinic in the coming years. Kriya Therapeutics is a fully integrated gene therapy company that combines proprietary computational tools, in-house GMP manufacturing, and a rational design toolkit to develop gene therapies. The company has scaled SIRVE™, a machine learning–enabled technology and cloud computing architecture, to integrate large datasets from high-throughput screening and sequencing. Kriya has expanded its pipeline via internal R&D, acquisitions, and partnerships, with therapeutic divisions in ophthalmology, oncology, rare disease, and chronic disease. It operationalized scalable GMP manufacturing infrastructure in Research Triangle Park, North Carolina to support in-house production from early through late-phase development. The company’s stated mission is to improve speed to market and reduce cost for gene therapies by advancing engineering, production, and translation capabilities. Proceeds from the recent financing will support advancing the pipeline and continued scaling of its engineering, manufacturing, and computational platforms. Kriya Therapeutics is a fully integrated platform company focused on designing, developing and manufacturing gene therapies. The company combines computational vector design (SIRVE™) and a proprietary high-efficiency manufacturing platform (STRIPE™) to reduce immunogenicity, improve expression and achieve lower production costs at scale. STRIPE is being developed at a 51,000 square foot manufacturing facility in Research Triangle Park, N.C., and Kriya expects its full cGMP manufacturing infrastructure to be online this year. Kriya is advancing an internal pipeline with programs in metabolic disease, ophthalmology and oncology. Proceeds from the recent financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance current programs. The company maintains locations in Silicon Valley/Redwood City, Calif., and Research Triangle Park, N.C., and is led by co-founder and CEO Shankar Ramaswamy, M.D. Kriya Therapeutics is a Palo Alto, Calif. and Durham, N.C.-based gene therapy company focused on expanding gene therapy beyond rare monogenic disorders to diseases that affect millions. Its pipeline centers on multiple AAV-based investigational therapies targeting metabolic diseases, including type 1 diabetes, type 2 diabetes, and severe obesity. Lead programs are KT-A112 (intramuscular delivery of genes producing insulin and glucokinase), KT-A522 (salivary gland delivery of a GLP-1 receptor agonist), and KT-A832 (intrapancreatic delivery of modified IGF-1). The company intends to use proceeds from its financing to develop these gene therapies. Kriya completed a seed round in Q4 2019 led by Transhuman Capital, which also participated in the Series A. The company is led by co-founder, chairman and CEO Shankar Ramaswamy, M.D., supported by a team of scientific, development, manufacturing, and regulatory executives.

Total raised

$921M

Funding rounds

5

Latest round

Series D

Latest activity

Sep 2025